サポート>ブログ>抗体医薬におけるドラッグデリバリーシステム(Drug Delivery Systems for Antibody-Based Therapies)

抗体医薬におけるドラッグデリバリーシステム(Drug Delivery Systems for Antibody-Based Therapies)

Biointron 2024-01-17
Antibody-Based-Therapies.jpg
Image credit: DOI: 10.1038/s41551-021-00698-w

Antibody-based therapies have emerged as powerful tools in the fight against cancer, providing targeted treatment options with reduced side effects. To further enhance their efficacy, researchers have been exploring the use of drug delivery systems (DDS) for the controlled release of antibodies. DDS would produce various benefits in drug efficacy, including improved convenience, reduced toxicity, and enhanced treatment outcomes.1 With the advancement of nanotechnology and increasing focus on antibody-related dosage forms, the development of advanced antibody delivery systems holds promise for cancer patients. 

Typically, antibody-based drugs are administered through intravenous routes, although there are risks with infusion-related reactions. To improve patient medication convenience, DDSs controlled release may use strategies such as subcutaneous injections, local depot formulations, inhalation powders, and oral systems.2 Another example are hydrogels, which studies have shown to be a potential DDS, controlling the release of antibody-streptavidin conjugates from the agarose-desthiobiotin hydrogels via controlled dissolution of sparingly soluble biotin derivatives.3 

At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References:

  1. Chen, Z., Kankala, R. K., Yang, Z., Li, W., Xie, S., Li, H., Chen, Z., & Zou, L. (2022). Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 12(8), 3719-3746. https://doi.org/10.7150/thno.72594

  2. Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020). Injectables and Depots to Prolong Drug Action of Proteins and Peptides. Pharmaceutics, 12(10). https://doi.org/10.3390/pharmaceutics12100999 

  3. Huynh, V., & Wylie, R. G. (2018). Competitive Affinity Release for Long-Term Delivery of Antibodies from Hydrogels. Angewandte Chemie International Edition, 57(13), 3406-3410. https://doi.org/10.1002/anie.201713428

Subscribe to our ブログ
Recommended Articles
人間の免疫システムの活用:自然な防御から精密医療へ

免疫・PAMP/DAMP・革新的抗体療法の解説

Aug 08, 2025
抗体薬物複合体(ADC)の基礎レビュー:作用機序、臨床進展、設計最適化、課題、および将来

抗体薬物複合体(Antibody-Drug Conjugates, ADC)は、がん治療において革新的なターゲット型治療薬の一つであり、モノクローナル抗体(mA……

Aug 05, 2025
抗体機能におけるFc糖鎖の役割

抗体の機能は、Fc領域の糖鎖修飾状態に大きく依存しています。

Jun 25, 2025
AIS 2025 – フランス:ハイライトとイベント総括

第13回抗体産業シンポジウム(Antibody Industrial Symposium 2025)が、2025年6月25日から26日にかけてフランス・トゥール……

Jun 22, 2025

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。